Recently, the Centers for Disease Control recommended the use of Preexposure prophylaxis (PrEP) commonly known by its brand name Truvada, for those at “high risk” of HIV infection; the drug which contains two antivirals, is currently approved and widely used in combination with other drugs to treat HIV in those already infected. According to the CDC, people at high risk who should be offered PrEP include about 1 in 4 sexually active gay and bisexual men, 1 in 5 people who inject drugs, and 1 in 200 sexually active heterosexual adults. Some scientists have warned that if an HIV-positive patient were to take Truvada alone, or if a user were to become infected while taking it, the HIV strains they carry could become drug-resistant. The infection would be hard to treat, and it could spread to other people.
From the CDC:
In 2010, the estimated number of new HIV infections among MSM was 29,800, a significant 12% increase from the 26,700 new infections among MSM in 2008.
Although MSM represent about 4% of the male population in the United States, in 2010, MSM accounted for 63% of all new infections. MSM accounted for 54% of all people living with HIV infection in 2011.
Since the epidemic began, an estimated 311,087 MSM with an AIDS diagnosis have died, including an estimated 5,380 in 2012.
Injection drug users represented 8% of new HIV infections in 2010 and 15% of those living with HIV in 2011. In 2012, there were 3,514 AIDS deaths among injection drug users.